表紙
市場調查報告書

質子幫浦抑制劑(PPI)的全球市場:2019年∼2023年

Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 881671
出版日期 內容資訊 英文 127 Pages
訂單完成後即時交付
價格
Back to Top
質子幫浦抑制劑(PPI)的全球市場:2019年∼2023年 Proton Pump Inhibitors (PPIs) Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年06月24日內容資訊: 英文 127 Pages
簡介

本報告提供全球質子幫浦抑制劑(PPI)市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • OTC PPI
  • 處方箋PPI
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 老年人口的增加
  • 肥胖盛行率的上升
  • PPI的使用率上升

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • 武田藥品工業

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31536

About this market

Proton pump inhibitors (PPIs) are drugs whose main mechanism is to inhibit the secretion of acid by the stomach, thus helping in reducing the symptoms of various acid-related diseases. Technavio's proton pump inhibitors (PPIs) market analysis considers sales from Over-the-counter (OTC) PPIs and prescription PPIs. Our analysis also considers the sales of proton pump inhibitors (PPIs) in Asia, Europe, North America, and ROW. In 2018, the OTC PPIs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy accessibility and affordability of OTC drugs will play a significant role in the OTC PPIs segment to maintain its market position. Also, our global proton pump inhibitors (PPIs) market report looks at factors such as reformulation of drugs and growth in prescription rates. However, the increasing lawsuits against PPIs, launch of generic PPIs, and stringent regulatory guidelines may hamper the growth of the proton pump inhibitors (PPIs) industry over the forecast period.

Overview

Reformulation of drugs

Vendors are trying to maintain their positions in the market by delaying the entry of generic versions and obtaining patent extensions through reformulation of drugs. This ensures the bioavailability of drugs and boosts patient compliance. The reformulation of already marketed drugs by vendors will lead to the expansion of the global proton pump inhibitors (PPIs) market at a CAGR of over 4% during the forecast period.

Rising prevalence of obesity

With the prevalence of obesity in older adults and children and adolescents, the risks to develop chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain types of cancer is also increasing. This is driving the need for PPIs for the treatment of these diseases, which is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global proton pump inhibitors (PPIs) market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global proton pump inhibitors (PPIs) market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proton pump inhibitors (PPIs) manufacturers, that include AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the proton pump inhibitors (PPIs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • OTC PPIs - Market size and forecast 2018-2023
  • Prescription PPIs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Growing geriatric population
  • Rising prevalence of obesity
  • Rising utilization of PPIs

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: OTC PPIs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: OTC PPIs - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Prescription PPIs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Prescription PPIs - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Use of PPIs in different patient settings in 2010
  • Exhibit 42: Sales of Takeda's PPIs after the launch of generics ($ millions)
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: AstraZeneca Plc - Vendor overview
  • Exhibit 50: AstraZeneca Plc - Product segments
  • Exhibit 51: AstraZeneca Plc - Organizational developments
  • Exhibit 52: AstraZeneca Plc - Geographic focus
  • Exhibit 53: AstraZeneca Plc - Key offerings
  • Exhibit 54: AstraZeneca Plc - Key customers
  • Exhibit 55: Bayer AG - Vendor overview
  • Exhibit 56: Bayer AG - Product segments
  • Exhibit 57: Bayer AG - Organizational developments
  • Exhibit 58: Bayer AG - Geographic focus
  • Exhibit 59: Bayer AG - Segment focus
  • Exhibit 60: Bayer AG - Key offerings
  • Exhibit 61: Bayer AG - Key customers
  • Exhibit 62: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 63: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 64: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 65: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 66: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 67: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 68: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 69: Pfizer Inc. - Vendor overview
  • Exhibit 70: Pfizer Inc. - Business segments
  • Exhibit 71: Pfizer Inc. - Organizational developments
  • Exhibit 72: Pfizer Inc. - Geographic focus
  • Exhibit 73: Pfizer Inc. - Segment focus
  • Exhibit 74: Pfizer Inc. - Key offerings
  • Exhibit 75: Pfizer Inc. - Key customers
  • Exhibit 76: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 82: Validation techniques employed for market sizing
  • Exhibit 83: Definition of market positioning of vendors
Back to Top